Literature DB >> 3000011

Epidermal growth factor receptors in normal and neoplastic thyroid tissue.

Q Y Duh, E T Gum, P L Gerend, S E Raper, O H Clark.   

Abstract

Epidermal growth factor (EGF) stimulates DNA synthesis and proliferation of thyroid cells in culture and may have an important role in the regulation of normal and neoplastic thyroid cell growth. We therefore studied paired normal and neoplastic thyroid tissue from eight patients for the presence of EGF receptors using a radioreceptor assay. 125I EGF binds to a particulate membrane fraction from both normal and neoplastic thyroid tissue with high affinity (dissociation constant ranged from 0.5 to 16.7 nmol/L). The binding is saturable, and maximal binding is achieved within 40 minutes at 37 degrees C and pH 7.5. This EGF binding is specific since it is competitively inhibited by unlabeled EGF but not by other hormones (thyrotropin, insulin, glucagon, and transferrin). The binding of EGF to thyroid neoplasms is higher than the binding to normal thyroid tissue (p less than 0.05). Thyroid tumors with a poorer prognosis appear to have higher EGF binding compared with adjacent normal thyroid tissue than have tumors with a better prognosis. EGF may have a role in the regulation of normal and neoplastic thyroid cell growth. Characterization of EGF receptors may help predict the clinical course of patients with malignant thyroid neoplasms.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3000011

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  16 in total

Review 1.  Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects.

Authors:  N J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 2.  Predictors of thyroid tumor aggressiveness.

Authors:  O H Clark
Journal:  West J Med       Date:  1996-09

3.  Analysis of epidermal growth factor (EGF) receptor and effect of EGF on the growth of cultured Graves' and non-neoplastic human thyroid cells.

Authors:  M Miyamoto; H Sugawa; K Kuma; T Mori; H Imura
Journal:  J Endocrinol Invest       Date:  1989-02       Impact factor: 4.256

4.  Aberrations of growth factor control in metastatic follicular thyroid cancer in vitro.

Authors:  T Hoelting; A Zielke; A E Siperstein; O H Clark; Q Y Duh
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

5.  Expression of PACAP and PAC1 Receptor in Normal Human Thyroid Gland and in Thyroid Papillary Carcinoma.

Authors:  Sebastian Bardosi; Attila Bardosi; Zsuzsanna Nagy; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2016-08-26       Impact factor: 3.444

6.  Effect of somatostatin on adenylate cyclase activity in normal and neoplastic thyroid tissue.

Authors:  A E Siperstein; K E Levin; E T Gum; O H Clark
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

7.  Epidermal growth factor receptors and adenylate cyclase activity in human thyroid tissues.

Authors:  Q Y Duh; A E Siperstein; R A Miller; J J Sancho; M J Demeure; O H Clark
Journal:  World J Surg       Date:  1990 May-Jun       Impact factor: 3.352

8.  Increased binding capacity of receptors for the epidermal growth factor in benign thyroid nodules and thyroid malignancies.

Authors:  B Saller; G Stapfer; B Bein; R Hoermann; F Spelsberg; K Mann
Journal:  Clin Investig       Date:  1993-11

9.  RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.

Authors:  Michelle Croyle; Nagako Akeno; Jeffrey A Knauf; Doriano Fabbro; Xu Chen; Jacqueline E Baumgartner; Heidi A Lane; James A Fagin
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

10.  Medullary thyroid carcinoma: targeted therapies and future directions.

Authors:  Scott N Pinchot; Muthusamy Kunnimalaiyaan; Rebecca S Sippel; Herbert Chen
Journal:  J Oncol       Date:  2009-12-24       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.